Trial Profile
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Lapatinib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions
- 22 Oct 2011 New trial record